Urology
Volume 75, Issue 5 , Pages 1144-1148 , May 2010

Efficacy and Safety of Tolterodine Extended Release and Dutasteride in Male Overactive Bladder Patients With Prostates >30 Grams

  • Doreen E. Chung

      Affiliations

    • Weill Cornell Medical College, Cornell University, New York, New York
    • Corresponding Author InformationReprint requests: Doreen E. Chung, M.D., F.R.C.S.C., Weill Cornell Medical College, Cornell University, 1300 York Ave., Box 261, Suite F9 West, New York, NY 10065
    • ,
  • Alexis E. Te

      Affiliations

    • Weill Cornell Medical College, Cornell University, New York, New York
    • ,
  • David R. Staskin

      Affiliations

    • Caritas St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Steven A. Kaplan

      Affiliations

    • Weill Cornell Medical College, Cornell University, New York, New York

Received 21 September 2009 ,Accepted 8 December 2009.

References 

  1. Irwin D, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1314
  2. Sexton C, Coyne K, Kopp Z, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009;103:12–33
  3. Hyman M, Groutz A, Blaivas J. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001;166:550–552
  4. Laniado M, Ockrim J, Marronaro A, et al. Serum prostate specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int. 2004;94:1283–1286
  5. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology. 2003;61:37–49
  6. Abdel-Aziz K, Lemack G. Overactive bladder in the male patient: bladder, outlet, or both?. Curr Urol Rep. 2002;3:445–451
  7. de Groat W. A neurologic basis for the overactive bladder. Urology. 1997;50:36–52
  8. Brading A, Turner W. The unstable bladder: towards a common mechanism. Br J Urol. 1994;73:3–8
  9. Drake M, Mills I, Gillespie J. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet. 2001;358:401–403
  10. Blake-James B, Rashidian A, Ikeda Y, et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int. 2007;99:85–96
  11. Chapple C, Roehrborn C. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651–659
  12. Knutson T, Edlund C, Fall M, et al. BPH with coexisting overactive bladder dysfunction—an everyday urological dilemma. Neurourol Urodyn. 2001;20:237–247
  13. Roehrborn C, McConnell J, Barry M, et al. Guideline on the Management of Benign Prostatic Hypertrophy (BPH): AUA Clinical Guidelines. 2006;
  14. Chapple C. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int. 2004;94:738–744
  15. McGuire E. Neuromuscular dysfunction of the lower urinary tract. In:  Walsh P,  Gittes R,  Perlmutter A, et al. editor. Campbell's Urology. Philadelphia, PA: W. B. Saunders; 1986;
  16. Kaplan S, Roehrborn C, Rovner E, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319–2328
  17. Kaplan S, Walmsley K, Te A. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2008;179:S82–S85
  18. Abrams P, Kaplan S, De Koning Gans H, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175:999–1004
  19. Lee J, Kim H, Lee S, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94:817–820
  20. Roehrborn C, Kaplan S, Jones J, et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effect of prostate size. Eur Urol. 2009;55:472–481
  21. Roehrborn C, Kaplan S, Kraus S, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008;72:1061–1607
  22. Coyne K, Matza L, Kopp Z, Abrams P, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49:1079–1086
  23. Irwin D, Milsom I, Kopp Z, et al. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009;56:14–20
  24. Coyne K, Sexton C, Irwin D, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–1395
  25. Emberton M, Neal D, Black N, et al. The effect of prostatectomy on symptom severity and quality of life. Br J Urol. 1996;77:233–247
  26. Housami F, Abrams P. Persistent detrusor overactivity after transurethral resection of the prostate. Curr Urol Rep. 2008;9:284–290
  27. Johnson T, Jones K, Williford W, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the department of veterans affairs cooperative study trial. J Urol. 2003;170:145–148
  28. Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009;56:534–541
  29. Van Venrooij G, Van Melick H, Eckhardt M, et al. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol. 2002;168:605–609
  30. MacDiarmid S, Peters K, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized double-blind placebo-controlled study. Mayo Clin Proc. 2008;83:1002–1010

PII: S0090-4295(09)03070-2

doi: 10.1016/j.urology.2009.12.010

Urology
Volume 75, Issue 5 , Pages 1144-1148 , May 2010

Article Tools

* Image Usage & Resolution